Bu H Z, Poglod M, Micetich R G, Khan J K
Department of Biopharmaceutics and Pharmacokinetics, Naeja Pharmaceuticals Inc., 4290-91A Street, Edmonton, AB, T6E 5V2, Canada.
J Mass Spectrom. 1999 Nov;34(11):1185-94. doi: 10.1002/(SICI)1096-9888(199911)34:11<1185::AID-JMS879>3.0.CO;2-R.
This paper presents liquid chromatography/mass spectrometry (LC/MS) and liquid chromatography/tandem mass spectrometry (LC/MS/MS) approaches for the rapid characterization of three urinary isomeric metabolites and their two precursor metabolites of SYN-2836, a novel antifungal agent, in dogs administered multiple oral doses of the agent (30 mg kg(-1) day(-1)). A collection of correlative data regarding the SYN-2836 metabolites was obtained by LC/MS and LC/MS/MS performed under complementary conditions such as the columns (C(18) vs cyano type), the mobile phase systems (acetonitrile-water-formic acid vs acetonitrile-water-ammonium acetate) and the electrospray ionization modes (positive vs negative). Metabolite identification was accomplished based on not only the LC/MS/MS data (product ion spectra) but also the LC/MS data indicating chromatographic behaviors of the metabolites. SYN-2836 and SYN-2869, an analog of the former, showed almost the same metabolic pathways following the same multiple-dose administration of the individual agents to the dogs. Therefore, correlation analysis in product ion spectra between corresponding metabolites of SYN-2836 and SYN-2869, and also in metabolic pathways between the two agents, was strategically used to facilitate the identification of the SYN-2836 (and SYN-2869 if necessary) metabolites. For the reason that various elucidation strategies were used complementarily, the chemical structures of the metabolites were unambiguously attained and the isomeric metabolites were explicitly differentiated without the use of other analytical methods. The methodologies used in this study may be applicable to metabolite screening of several structurally related agents simultaneously, promoting lead finding and optimization of drug candidates using a metabolism-based approach.
本文介绍了液相色谱/质谱联用(LC/MS)和液相色谱/串联质谱联用(LC/MS/MS)方法,用于快速表征新型抗真菌药物SYN - 2836在犬体内多次口服给药(30 mg kg⁻¹ day⁻¹)后的三种尿中异构代谢物及其两种前体代谢物。通过在互补条件下(如色谱柱(C₁₈对氰基型)、流动相系统(乙腈 - 水 - 甲酸对乙腈 - 水 - 醋酸铵)和电喷雾电离模式(正离子对负离子))进行LC/MS和LC/MS/MS,获得了关于SYN - 2836代谢物的一系列相关数据。代谢物鉴定不仅基于LC/MS/MS数据(产物离子谱),还基于指示代谢物色谱行为的LC/MS数据。SYN - 2836及其类似物SYN - 2869在对犬进行相同的多次给药后显示出几乎相同的代谢途径。因此,战略性地利用SYN - 2836和SYN - 2869相应代谢物的产物离子谱相关性分析以及两种药物之间的代谢途径相关性分析,以促进SYN - 2836(必要时还有SYN - 2869)代谢物的鉴定。由于各种阐明策略互补使用,无需使用其他分析方法即可明确获得代谢物的化学结构并明确区分异构代谢物。本研究中使用的方法可能适用于同时对几种结构相关药物进行代谢物筛选,促进基于代谢方法的先导化合物发现和药物候选物优化。